The Department of Health – Abu Dhabi (DoH) has launched a revolutionary treatment for Pulmonary Arterial Hypertension, positioning Abu Dhabi as the first in the region to offer this advanced medication.
Known as WINREVAIR, the medication is administered via subcutaneous injection every three weeks and can be self-administered under medical supervision. By targeting specific pathways that cause excessive cell growth in the pulmonary blood vessels, WINREVAIR helps improve blood flow and reduce strain on the cardiovascular system.
Developed by biopharmaceutical leader MSD, WINREVAIR complements standard therapies to lower mortality risks for patients at low to moderate risk levels. Clinical trials have shown that this treatment can reduce the likelihood of severe health events by 84 percent, improve exercise capacity, and extend patients’ life expectancy by over a decade when combined with other treatments.
Approved by the US FDA and the European Medicines Agency, this milestone reflects Abu Dhabi’s commitment to enhancing healthcare outcomes. Pulmonary Arterial Hypertension affects 15 to 60 people per million globally, predominantly women aged 50 to 65.
